PROGRAM LIVE SITES
- Meeting Information
- Course Directors
- Scientific Committee
- Associations and Affiliations
- TCTAP Live Interviews
- Daily Newspaper
- TCTAP Gallery



April 27 (Wed.), 2011
Paradigm Shift to Functional Angioplasty
New Insights for FFR and IVUS guided PCI
Dr. Park will present the new insight for FFR and IVUS guided PCI. In real world practice, fewer than half of all patients are non-invasively evaluated for myocardial ischemia prior to revascularization therapy. Thus, coronary angiograms are still frequently utilized as a cornerstone of decision aking, despite the substantial discrepancy between the angiographic and functional severity of stenosis. Adjuvant technologies such as fractional flow reserve (FFR) and intravascular ultrasound (IVUS) are therefore considered in daily practice to overcome the limitations of coronary angiography for diagnostic and interventional procedures.
Today, he will propose the concept of functional angioplasty, simultaneous utilization of FFR and IVUS in daily practice in contemporary catheterization laboratories.......
What's New in 2011!!!
TCTAP Highlights
TCTAP Highlights 1: Meet the Experts over Breakfast
7:00 AM to 8:10 AM, Wednesday April 27th through Friday April 29th
TCTAP Highlights 2: Technology & Innovation
6:00 PM to 9:00 PM, Tuesday April 26th
TCTAP Highlights 3: Fellows Course
2:00 PM to 5:00 PM, Tuesday April 26th
TCTAP Highlights 4: The Most Distinguished Studies of 2010- 2011 in Interventional and Clinical Cardiology: Meet the Authors and Discuss with the Experts
8:30 AM to 12:30 PM, Thursday April 28th
New for 2011
1. Poster zone
2. TCTAP2011 Mobile Application
3. Master of the Masters .....
Hopes for Patients Who Cannot Undergo AVR: TAVI
In the 16th Angioplasty Summit 2011- TCTAP has the program about the latest technical and clinical investment about transcatheter aortic valve implantation (TAVI). On Wednesday morning,at 9:40
AM in the Main Arena, "The TAVI Revolution" will be held. In addition, at 2:00 PM, Wednesday, in the Coronary Arena, there will be a "Transcatheter Valve
Therapy" session covering from the patient selection to the cost-effectiveness of the TAVI.
Until now, surgical aortic valve replacement (AVR) is currently the only treatment option for severe aortic stenosis that has been shown to improve survival.
Unfortunately, up to one third of patients with severe aortic stenosis are ineligible for AVR, either because of advanced age or the presence of multiple comorbidities.
Recently, TAVI is becoming another option for the patients who are not operative candidates.
Since the first successful human case of TAVI in 2002 by Cribier et al., the combination of technology enhancements, revised patient selection, and improved operator techniques have resulted in reduced procedural complications and improved clinical outcomes.

Current Valves in TAVI

There are currently two valves in clinical use. One is the Edwards transcatheter heart valve (Edwards Lifesciences, Irvine, CA) which utilizes a balloon-expandable tubular frame and the other is selfexpandable CoreValve.....